靶向药物治疗套细胞淋巴瘤的研究进展

套细胞淋巴瘤(MCL)是一种少见的非霍奇金淋巴瘤亚型.MCL临床表现有两种类型:一种为惰性表现,病情进展缓慢;另一种为侵袭性表现,病程进展迅速.近年,一些用于MCL治疗的新靶向药物已经问世.这些靶向药物较常规化疗提高了对复发/难治性MCL的疗效,其治疗MCL的靶点为B细胞淋巴瘤表面抗原、B细胞受体信号和肿瘤细胞微环境等.文章介绍了MCL靶向药物的研究进展.

Research progress of targeted agents in the treatment of mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma.The MCL is classified into two subtypes, some patients have a chronic/indolent course and the others have a more aggressive course and short survival.In recent years, some novel therapeutic target agents for MCL have reports.These target agents achieve efficacy comparable to conventional chemotherapy in relapsed/refractory MCL.Therapeutic targents for MCL include the surface antigens of B-cell lymphoma, B-cell receptor signaling, DNA damage response pathway and the cellular microenviroment.This review focused on the recent research progress of target agents in the treatment of MCL.